Compare Inovio Pharmaceuticals Inc (INO) vs Newmont Corporation (NEM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Newmont Corporation — how do they compare? Inovio Pharmaceuticals Inc trades at $1.09 (market cap $89.27M), while Newmont Corporation trades at $92.51 (market cap $95.23B). The key difference: Newmont Corporation is far larger — about 1066.8× Inovio Pharmaceuticals Inc's market cap, and Newmont Corporation pays a 1.17% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| INO | NEM | |
|---|---|---|
Market Cap | $89.27M | $95.23B |
Sector | Health | Basic Materials |
52-Week High | $2.87 | $131.95 |
52-Week Low | $1.05 | $59.86 |
Enterprise Value | $60.28M | $91.98B |
Dividend Yield | — | 1.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.07, down 4.46% today, reflecting persistent bearish technical signals. The company shows minimal revenue of $65.34K (2025) with a net loss of $84.95M, resulting in a negative net margin of 130,000%. Despite beating recent EPS estimates, cash flow remains negative. Key near-term catalyst is the FDA's PDUFA decision on INO-3107 by October 30, 2026.
Outlook hinges on regulatory success for INO-3107; approval could drive significant upside, but failure poses substantial risk. High cash burn and lack of profitability underscore speculative nature. Analyst consensus is cautiously optimistic with 53% buy ratings, yet financial health remains precarious without near-term revenue growth.
Newmont Corporation (NEM) trades at $89.52, down 0.2% over 24 hours, with technical indicators showing a bearish trend. The company reported strong fundamentals with Q1 2026 EPS of $2.90 beating expectations of $2.07, revenue growth to $22.67 billion in 2025, and robust cash flow from operations of $10.33 billion. Analyst sentiment remains overwhelmingly positive with 28 buy ratings and a consensus price target of $139.22, suggesting significant upside potential from current levels.
The outlook for Newmont is favorable due to strong earnings momentum, attractive valuation multiples (P/E of 11.63), and projected revenue growth to $25.0 billion in 2026. Key risks include exposure to gold price volatility, rising unit costs pressuring margins, and execution challenges in production growth. The stock presents a compelling opportunity for value-oriented investors given the disconnect between current price and analyst targets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Newmont Corporation
Newmont Corp is primarily a gold producer with operations and/or assets in the United States, Canada, Mexico, Dominican Republic, Peru, Suriname, Argentina, Chile, Australia, and Ghana. It is also engaged in the production of copper, silver, lead and zinc. The company's operations are organized in five geographic regions: North America, South America, Australia, Africa and Nevada.
Read more on NEM →
